Elena Yuryevna Esina

Elena Yuryevna Esina

Auto-generated profile, based on publicly available information

Elena Yuryevna Esina

Voronezh State Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Juvenis scientia
Verified
Journal Article
Open access
PDF file
SLSvetlana Lagutina
Svetlana Lagutina
PCP. A. Chizhkov
P. A. Chizhkov
АЗА.а. Зуйкова
А.а. Зуйкова
EEE. Yu. Esina
E. Yu. Esina
IDI. S. Dobrynina
I. S. Dobrynina
MSMikhail Syromyatnikov
Mikhail Syromyatnikov
Введение. Воспалительные заболевания кишечника (ВЗК) занимают лидирующие позиции в структуре заболеваний желудочно-­кишечного тракта (ЖКТ), так как являются прогрессирующей хронической патологией с аутоиммунным типом воспаления. Изменение показателей микробиоты кишечника может определять морфологические изменения на латентном этапе заболевания. Цель исследования. Оценка родо-видового биоразнообразия микробиоты у пациентов с ВЗК. Пациенты и методы. Выполнено секвенирование 16S рРНК микробиоты кишечника у 15 пациентов с подтвержденным язвенным колитом (ЯК) и 20 здоровых лиц, которые являлись контрольной группой. Проведен анализ показателей общего анализа крови и уровня С-реактивного белка (СРБ). Для статистического анализа использовали программы Microsoft Excel и Statistica. Результаты. Среди исследуемых лабораторных показателей у пациентов с ВЗК было отмечено значительное увеличение уровня СРБ, лейкоцитов и нейтрофилов по сравнению с группой контроля. В результате секвенирования кишечной микробиоты у пациентов с ВЗК выявлено снижение нормобиоты, а также увеличение содержания представителей патогенного кластера. Заключение. Выявлено снижение биоразнообразия микробиоты у пациентов с ВЗК по сравнению с группой контроля. Также наблюдалось значимое изменение патогенного кластера и дисбаланс представителей Bacteroidetes и Firmicutes. Introduction. Inflammatory bowel diseases (IBD) occupy a leading position in the structure of diseases of the gastrointestinal tract (GIT), as they are a progressive chronic pathology with an autoimmune type of inflammation. Changes in the composition of the gut microbiota can determine morphological changes at the latent stage of the disease. Aim of the study. To assess the genus-­species biodiversity of the microbiota in patients with IBD. Patients and methods. 16S rRNA sequencing of the intestinal microbiota was performed in 15 patients with confirmed ulcerative colitis (UC) and 20 healthy controls. The parameters of the full blood count and the serum level of C-reactive protein (CRP) were analyzed. The analysis of the obtained data was carried out using Microsoft Excel and Statistica software. Results. Among the studied laboratory parameters in patients with IBD, there was a significant increase in CRP, leukocyte and neutrophil counts compared to the control group. Sequencing of the gut microbiota showed a decrease in the normobiota, as well as an increase in the representatives of the pathogenic cluster. Conclusion. In the present study, we demonstrated a decrease in the biodiversity of the gut microbiota in patients with IBD compared to the control group, a significant change in the pathogenic cluster, and an imbalance between the representatives of Bacteroidetes and Firmicutes.

14 March 2025 in Лечащий врач
Verified
Journal Article
Closed access
NSN.A. Starodubtseva
N.A. Starodubtseva
EEE.YU. Esina
E.YU. Esina
YKY.A. Kotova
Y.A. Kotova
APA.A. Pashkova
A.A. Pashkova
Background. In the modern world, non-alcoholic fatty liver disease is a serious health problem in all countries. This disease is becoming more common. Large-scale studies and generalized data analyses have revealed that non-alcoholic fatty liver disease may be associated with an increased risk of cardiovascular diseases and their complications. Objective. To review current publications and articles on the impact of non-alcoholic fatty liver disease on the development and course of cardiovascular diseases. Materials and methods. As part of the study, materials from Russian and foreign sources devoted to this topic were studied and analyzed. The literature was searched in databases such as PubMed, RSCI and eLibrary. Results. Non-alcoholic fatty liver disease and chronic heart failure with preserved ejection fraction are systemic diseases. Every year the number of scientific papers increases, which indicate a close relationship between non-alcoholic fatty liver disease and chronic heart failure with preserved ejection fraction, an independent correlation has been established between the presence of non-alcoholic fatty liver disease and an increase in the risk of occurrence and progression of chronic heart failure with preserved ejection fraction in the long term. In the Russian and foreign literature, there is evidence of a link between elevated insulin levels, overweight, the role of oxidative stress, impaired fat metabolism and damage to the inner lining of blood vessels. An increase in the amount of free fatty acids in the body can provoke the accumulation of lipids in the heart muscle, which can further cause problems with the functioning of the left ventricle. It is worth noting that changes in myocardial metabolism are associated with impaired energy processes in the cells of the heart muscle, a decrease in adenosine triphosphate levels, oxygen starvation of tissues and impaired electrical activity. Conclusions. Oxidative stress, chronic inflammation, insulin immunity, endothelial dysfunction and adipocytokine disorders are the main factors that can increase the risk of chronic heart failure in non-alcoholic fatty liver disease. Taking into account all of the above, non-alcoholic fatty liver disease can be considered an additional risk factor for chronic heart failure.

26 May 2021 in Cardiosomatics
Verified
Journal Article
Open access
PDF file
YKYuliya A. Kotova
Yuliya A. Kotova
AZAnna A. Zuikova
Anna A. Zuikova
NSNatalia V. Strahova
Natalia V. Strahova
OKOlga N. Krasnorutskaya
Olga N. Krasnorutskaya
EEElena Y. Esina
Elena Y. Esina
Aim. To study the role of markers of endothelial dysfunction, oxidative and cellular stress in the prediction of myocardial infarction (MI) in comorbid patients with stable coronary heart disease (CHD). Material and methods. The study involved 336 patients with a diagnosis of CHD. The presence of CHD was confirmed by diagnostic coronary angiography with the calculation of the Gensini index. All patients were divided into 2 groups: group 1288 patients without a history of MI, group 248 patients with a history of MI. All patients were assessed for the levels of oxidized modified proteins, high-sensitivity C-reactive protein (hs-CRP), homocysteine, heat shock protein (HSP70), and superoxide dismutase activity. Results. All patients were comparable in age. For other clinical and anthropometric characteristics, we saw significant differences (according to the MannWhitney criterion): patients with previous MI had higher BMI, waist circumference, and blood pressure. The correlation analysis revealed positive significant average strength relationships between past MI and the Gensini index, low-density lipoprotein level, total cholesterol level, homocysteine level, hs-CRP level, and the level of oxidized modified proteins; and negative significant average strength relationships between past MI and SOD activity level (r=-0.374, p=6.4 E-07) and HSP70 level (r=-0.563, p=2.6 E-15). The ROC analysis revealed that not all markers were significant in predicting the risk of MI. It is shown that the most expected characteristics were shown by the hs-СRP. However, further analysis of the predictive significance of the markers demonstrated that the addition of HSP70 to hs-CRP increases the predictive significance of hs-CRP in relation to the risk of developing MI. Conclusion. We have demonstrated that a strategy using a cumulative risk assessment consisting of 2 biomarkers (individually involved in inflammation and stress-induced cellular responses) can identify patients with an established diagnosis of CHD who have an increased risk of acute MI.

23 April 2024 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
YMYu.A. Matasova
Yu.A. Matasova
EEE.YU. Esina
E.YU. Esina
SLSvetlana Lagutina
Svetlana Lagutina
OSO.S. Skuratova
O.S. Skuratova
APA.A. Pashkova
A.A. Pashkova
IDI.S. Dobrynina
I.S. Dobrynina
The frequency of chronic kidney disease (CKD) in the structure of noncommunicable diseases is constantly rising. The number of patients on substitutive renal therapy is increasing. The progression of CKD, the development of drug resistance, and anxiety-depressive states during long-term therapy deteriorate the quality of life (QoL) of patients. Objective. To assess the risk of developing fractures and sarcopenia and the QoL of patients with CKD at the outpatient stage. Materials and methods. Forty (40) patients with established CKD diagnosis were examined at the outpatient stage. The average of patients was 56.5±11.2 years. The examination included total blood count, blood biochemistry, and QoL assessment using the questionnaires: SARC-f (for sarcopenia signs), MMSE (Mini-Mental State Examination), FRAX (fracture risk assessment tool), and EQ-5D (QoL assessment tool). Statistical data processing was performed using the Statistics software; the indicators were considered statistically significant at p<0.05. Results. 75% of patients with CKD had hypertensive disease (hypertensive nephroangiosclerosis) as a comorbidity. 62% (n=87) had anemic syndrome of varying severity. The QoL assessment revealed moderate/high risk of falls and fractures in 15% (n=21), sarcopenia signs in 35% (n=49), and altered mental state with mild/moderate disorders in 67% (n=94) of cases. Conclusion. We established a statistically significant decrease in QoL indicators (physical and psychological components) in patients with CKD at the outpatient stage, as well as a high risk of other pathological conditions (mineral-bone disorders). This evidence urges timely correction of drug and non-drug therapy and close monitoring at the outpatient stage.

19 September 2023 in Pediatrician (St. Petersburg)
Verified
Journal Article
Closed access
PDF file
SLSvetlana Lagutina
Svetlana Lagutina
OSOlga S. Skuratova
Olga S. Skuratova
PCPavel A. Chizhkov
Pavel A. Chizhkov
AZAnna A. Zuykova
Anna A. Zuykova
AKAnastasia S. Kurguzova
Anastasia S. Kurguzova
KSKirill D. Samkov
Kirill D. Samkov
MayerRokitanskyKstnerHauser syndrome is a congenital anomaly in the development of the female reproductive system, the essence of which is a violation of the intrauterine development of the Mllerian ducts, causing complete aplasia of the vagina and uterus. Deviation is a total or partial absence uterus, two upper thirds of the vagina, most often in combination with various anomalies of organs and systems, such as excretory, cardiovascular. Currently, the causes of this pathology are not fully understood studied. According to the World Health Organization, the percentage of hereditary factors intrauterine development disorders is approximately 10 to 25%. It is known that patients with this pathology often suffer from diseases of the urinary system (pyelonephritis). Chronic pyelonephritis is a common pathology in any age group due to excessive growth of the bacterial flora. The main causative agent, most often, are representatives of the intestinal microbiota (Escherichia coli, Enterococcus, Staphylococcus). Determination of the genus and species composition of the intestinal microbiota can serve as one of the diagnostic signs that contribute to the timely correction of the main therapy. Presented clinical case demonstrates a change in the biodiversity of the intestinal microbiota in a patient with MayerRokitanskyKstnerHauser syndrome, which entails timely correction of drug therapy regimens in relation to chronic pyelonephritis and achieving remission. Thus, the study of changes in the composition of the intestinal microflora can become a new criterion in the diagnosis and treatment of this disease at an early stage.

28 December 2025 in Journal of Clinical Practice
Verified
Journal Article
Open access
LKLubov Sergeevna Kiseleva
Lubov Sergeevna Kiseleva
EEElena Yuryevna Esina
Elena Yuryevna Esina
IMIrina Vladimirovna Makedonskaya
Irina Vladimirovna Makedonskaya
BACKGROUND: Left ventricular noncompaction cardiomyopathy is one of the rare forms of primary cardiomyopathy with an unfavorable prognosis and disease course. The mortality among the adult population is approximately 50%. The clinical signs are not specific and the diagnostics in some cases takes a long period of time. In this article, based on an example of one of the variants of cardiomyopathy development, a path of setting the diagnosis and adjusting the treatment in real-life clinical practice is described. CLINICAL CASE DESCRIPTION: In the patient with a noncompaction cardiomyopathy in the left ventricle, the leading clinical symptoms were the complex cardiac rhythm disorders (ventricular extrasystoles of high grade, paroxysmal-persistent form of atrial fibrillation and flutter), the development and the progression of cardiac failure with the decreased ejection fraction down to 22%. The adjustment of the antiarrhythmic and the pulse-decreasing therapy was done, as well as the attempts of medicinal stabilization of the course of cardiac failure. Due to the inefficiency of conservative therapy with the development of uncontrolled rhythm disorders and the terminal cardiac failure, the orthotopic heart transplantation was carried out. CONCLUSION: The presented clinical case demonstrates a variation of the progressive course of the left ventricular noncompaction cardiomyopathy with the development of terminal cardiac failure within 4 years after the onset of the disease, requiring the heart transplantation. The clinicists and the functional and ultrasonic diagnostics specialists need to be aware of the rare forms of cardiomyopathies, including the asymptomatic variants, for the timely diagnostics and for adequate treatment.